Crenigacestat is under clinical development by Eli Lilly and Co and currently in Phase I for Natural Killer Cell Lymphomas. According to GlobalData, Phase I drugs for Natural Killer Cell Lymphomas does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Crenigacestat LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Crenigacestat overview
Crenigacestat (LY-3039478) is under development for the treatment of adenoid cystic carcinoma, soft tissue sarcoma, metastatic colon cancer, metastatic hepatocellular carcinoma, cholangiocarcinoma, chronic lymphocytic leukemia, leiomyosarcoma, natural killer (NK) cell neoplasm, glioblastoma, B-cell lymphoma, gastrointestinal stromal tumours (GIST), T-cell lymphoblastic lymphoma (T-LBL). The drug candidate is a new chemical entity (NCE). It is administered orally and intravenously. It targets Notch 1 receptor, and gamma-secretase. It was under development for the treatment of metastatic triple negative breast cancer, T-cell acute lymphoblastic leukemia (T-ALL) and refractory/relapsed multiple myeloma.
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company operates R&D facilities, and production and distribution facilities in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
For a complete picture of Crenigacestat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
